Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA)
India
· Delayed Price · Currency is INR | Market Cap | 4.16T |
| Revenue (ttm) | 516.03B |
| Net Income (ttm) | 114.34B |
| Shares Out | 2.40B |
| EPS (ttm) | 47.71 |
| PE Ratio | 36.36 |
| Forward PE | 35.80 |
| Dividend | 15.50 (0.90%) |
| Ex-Dividend Date | Feb 6, 2025 |
| Volume | 1,956,730 |
| Average Volume | 2,204,488 |
| Open | 1,731.45 |
| Previous Close | 1,731.45 |
| Day's Range | 1,705.20 - 1,741.35 |
| 52-Week Range | 1,377.20 - 1,960.35 |
| Beta | 0.54 |
| RSI | 54.96 |
| Earnings Date | May 22, 2025 |
About NSE:SUNPHARMA
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology, neuropsychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, ophthalmology, orthopaedic, nephrology, dental, and othe... [Read more]
Financial Performance
In 2023, NSE:SUNPHARMA's revenue was 484.97 billion, an increase of 10.51% compared to the previous year's 438.86 billion. Earnings were 95.76 billion, an increase of 13.01%.
Financial StatementsNews
Nifty 50 top losers today, March 27: Tata Motors, Sun Pharmaceutical, Eicher Motors, Apollo Hospitals and more
The Indian equity markets continued their bullish momentum on March 27, with benchmark indices ending the trading session on a positive note. The Nifty 50 closed at 23,591.95, gaining 105.10 points (0...
Sun Pharma share price: HSBC sees 21% upside, maintains ‘Buy’; bullish on Checkpoint Therapeutics acquisition
HSBC has reiterated its ‘Buy’ rating on Sun Pharma, setting a target price of ₹2,000, indicating a 21% upside from the current market price of ₹1,657 (as of March 11). The brokerage remains optimistic...
Stock Market news: Bharti Airtel, Zydus Life, Bharat Forge, Tata Motors, Sun Pharma among stocks to watch today on brokerage updates
Several stocks are in focus today following fresh brokerage reports. Key updates include Bharti Airtel’s tie-up with SpaceX’s Starlink, Zydus Life’s acquisition of Amplitude Surgical, and varied views...
Nifty 50 top gainers today, March 11: Trent, BPCL, Sun Pharmaceutical, ICICI Bank and more
The Indian equity indices closed on a flat note in a volatile session on March 11, 2024. The BSE Sensex dipped marginally by 12.85 points or 0.02 percent to settle at 74,102.32, while the NSE Nifty 50...
Sun Pharma share price: Nomura maintains ‘neutral’ rating, sets target at Rs 1,970 amid Checkpoint Therapeutics acquisition
Nomura has maintained a ‘neutral’ rating on Sun Pharmaceutical Industries Ltd, setting a target price of ₹1,970 per share. The brokerage highlighted Sun Pharma’s announcement to acquire Checkpoint The...
Stocks to Watch Today: IndusInd Bank, BEL, Sun Pharma, SBI Cards, Maruti in focus on brokerage updates
Indian stock markets are expected to remain volatile today, with several key stocks under focus based on fresh brokerage updates. Analysts have revised ratings, target prices, and highlighted emerging...
Sun Pharma to acquire US oncology compony for over Rs 3,000 crore
Sun Pharma, India's largest pharmaceutical company, is set to acquire Checkpoint Therapeutics for $355 million. This strategic acquisition will enhance Sun Pharma's specialty portfolio, including UNLO...
Checkpoint Agrees To Sun Pharma Buyout: This Deal Suits Both Parties
Checkpoint Therapeutics is being acquired by Sun Pharmaceutical for $4.10 per share. Learn why CKPT stockholders could earn an additional $0.7 with the CVR.
M&A Snapshot: Sun Pharma to acquire Nasdaq-listed Checkpoint Therapeutics for $355M
India's Sun Pharma buys onco-derman firm Checkpoint Therapeutics for $355M
Stocks to watch today, March 10: Sun Pharma, ONGC, JSW Steel, Biocon, Omaxe and more
The Indian stock market has been experiencing significant movement, with the BSE Sensex rising by 1,134.48 points (1.55%) and the NSE Nifty gaining 427.8 points (1.93%) last week. However, today, Gift...
HSBC cuts target price for Sun Pharma shares by Rs 280 to Rs 2,000
HSBC has maintained its ‘Buy’ rating on Sun Pharma but has lowered the target price to ₹2,000 from ₹2,280. The brokerage remains optimistic about the company’s growth prospects, particularly in the sp...
Macquarie bullish on select pharma and CDMO stocks, bearish on hospitals
Macquarie believes that the recent correction in pharma stocks due to US tariff threats provides an attractive buying opportunity, particularly in formulations and CDMO (Contract Development and Manuf...
HSBC on pharma stocks: US tariff concerns overdone; Sun Pharma, Torrent Pharma shares to see minimal impact
HSBC has stated that concerns regarding US tariffs on Indian pharmaceutical companies appear overdone, as Indian firms supply 60% of the generic drug volume to the US, playing a key role in cost reduc...
Nifty 50 top gainers today on February 13: Tata Steel, Sun Pharmaceutical, Bajaj Finserv, Bajaj Finance and more
Indian benchmark indices closed on a flat note on February 13, 2024, with the Nifty 50 maintaining its position above the crucial 23,000 mark. The Sensex declined slightly by 32.11 points (0.04%) to s...
Sun Pharma and Philogen announce completion of patient enrollment for Phase III FIBROSARC trial
The trial, conducted across Germany, France, Italy, Spain, and Poland, has exceeded its enrollment target with 129 patients enrolled against the planned 118. Key results from this study are anticipate...
Sun Pharma, Reliance Industries: Top stock recommendations for today
India Business News: Stock Recos by Brokers 040225BofA Securities has maintained its ‘buy’ recommendation on Reliance Industries with a target price of Rs 1,550 (+24%).
Sun Pharma shares in focus: Jefferies, HSBC bullish with up to 30% upside; CLSA cautious
Sun Pharmaceutical Industries shares are in the spotlight following strong Q3FY25 results, with Jefferies and HSBC maintaining bullish views, while CLSA remains cautious. The stock, currently trading ...
Budget 2025: Stocks in focus as Tata Power, Sun Pharma, IRCON, Aadhar Housing await key policy announcements
The Union Budget 2025 is expected to drive significant market movements today, with stocks from various sectors poised to react based on key policy announcements. Companies like Tata Power, Sun Pharma...
Stock market today: IndusInd Bank, ONGC, Sun Pharma, Bandhan Bank, Vishal Mega Mart among top stocks in focus amid Q3 results
The stock market is expected to remain active today as several companies that announced their Q3 results yesterday will be in focus, along with key developments from the Union Budget 2025. IndusInd Ba...
Sun Pharma Q3 FY25 Results: Net profit rises 24.1% YoY to Rs 3,219.6 crore, gross sales increase 10.5%
Sun Pharmaceutical Industries Limited has reported strong financial performance for the third quarter ending December 31, 2024 (Q3 FY25). The company recorded a 24.1% year-on-year (YoY) growth in adju...
Stocks Hitting 52-Week Low Today, January 29: Star Health, Tata Communications, BHEL, KPIT Technologies, Sun Pharma and more
Indian equity markets maintained their positive momentum, with both the Sensex and Nifty closing higher for the second consecutive session. The Sensex rose by 631.55 points (0.83%), closing at 76,532....
Nifty 50 top losers today on January 28: Sun Pharma, Britannia Industries, Hindalco Industries, Grasim Industries and more
Indian equity indices ended a two-day losing streak and closed higher, with the Nifty finishing at 22,957.25 and the Sensex climbing 535.24 points to 75,901.41. Despite this overall market recovery, s...
Sun Pharma’s subsidiary Taro to acquire Antibe Therapeutics
Sun Pharmaceutical Industries Limited, through its subsidiary TARO Pharmaceuticals Inc., has entered into an agreement to acquire 100% of Antibe Therapeutics Inc., a clinical-stage biotechnology compa...
Sensex jumps over 1,400 pts, best day in nearly 2 months
The sensex surged by 1,436 points, nearly reaching 80,000, driven by broad-based buying and short covering. Gains in banking, IT, auto and metal stocks also fuelled the rally amidst low foreign fund a...